FRUZAQLA® (fruquintinib) patient profiles*

Explore 2 potential mCRC patient types and learn how they may benefit from treatment with FRUZAQLA

Meet Barbara, a hypothetical 58-year-old patient with mCRC and liver metastasis.

Learn about Barbara’s treatment needs

Download Barbara’s Profile

Barbara*

58-year-old patient with mCRC and liver metastasis

Diagnosis

  • Diagnosed with unresectable left-sided mCRC 23 months ago
  • Presented with metastasis in multiple sites, including liver
  • Molecular profiling of primary tumor:
    • Microsatellite stable; MMR proficient with no actionable mutation

Treatment History

  • Initiated treatment with FOLFOX + bevacizumab
  • CT scans at 2 months and 4 months showed decreased size of liver lesions
  • CT scan at 14 months revealed disease progression
    • Greater degree of metastasis, with an increase in liver lesion size
    • Progressive disease in the lymph nodes
  • Subsequent treatment with FOLFIRI
  • Disease progression after 6 months on her most recent treatment, with evidence of new lesions and pulmonary metastasis

Next steps

Considerations

  • ECOG PS 1
  • ALT: 22UI/L; AST:25 IU/L (normal levels)
  • Would like to pursue more treatment

Barbara needs a treatment that

  • Extends survival while delaying or maintaining time to deterioration of symptoms
  • Has demonstrated prolongation of survival in patients with liver metastasis after 2 types of chemotherapy + bevacizumab
  • Satisfies her desire to make fewer visits to the hospital for treatment administration
  • Minimizes the impact of her treatment on her activities of daily life
     
Meet Mark, a hypothetical 64-year-old patient with mCRC presenting with myelosuppression

Learn about Mark’s treatment needs

Download Mark’s Profile

Mark*

64-year-old patient with mCRC presenting with myelosuppression

Diagnosis

  • Diagnosed with high-risk Stage III adenocarcinoma of the colon
  • Molecular profiling of primary tumor
    • Microsatellite stable; MMR-proficient with no actionable mutation

Treatment history

  • Surgery with 12 cycles of subsequent FOLFOX adjuvant therapy
  • CT scan 7 months after completion of adjuvant therapy revealed recurrence in the liver and progressive disease in lymph nodes
  • Initiated treatment with FOLFIRI + bevacizumab with progression after 4 months
  • Blood test results demonstrated:
    • Neutropenia (ANC 1200/mm3) that persisted for >30 days, eventually resolved with G-CSF
    • Thrombocytopenia (platelet count 110,000/mm3) that persisted for >30 days
       

Next steps

Considerations

  • ECOG PS 0
  • Need for disease control given the extent of distant metastasis
  • Would prefer minimal interference with current lifestyle

Mark needs a treatment that

  • Extends survival while delaying or maintaining time to deterioration of symptoms
  • Has demonstrated tolerability, particularly with a low risk of inducing myelosuppression
  • Offers convenient dosing that doesn’t require infusion center visits for treatment
  • Minimizes the impact of his treatment on his activities of daily life
     

Convenient, Once-Daily Oral Dosing

Discover simple, once-daily dosing with FRUZAQLA.

FRESCO-2 Efficacy Results

Learn about the efficacy results from FRESCO-2, a global, double-blind, placebo-controlled study with a heterogenous patient population.

FRESCO-2 Safety Profile

Explore the safety profile of FRUZAQLA from the FRESCO-2 clinical trial.

ALT=alanine aminotransferase; ANC=absolute neutrophil count; CT=computed tomography; ECOG PS=Eastern Cooperative Oncology Group performance status;
FOLFIRI=leucovorin calcium (folinic acid), fluorouracil, and irinotecan; FOLFOX=leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin; G-CSF=granulocyte-colony stimulating factor; MMR=mismatch repair; ULN=upper limit of normal.

*Hypothetical patient. Individual patient results may vary.

FRUZAQLA should not be used in patients with severe hepatic impairment (total bilirubin >3 times ULN and any AST). Please see full Prescribing Information for more information.1